GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marizyme Inc (OTCPK:MRZM) » Definitions » Net Change in Cash

Marizyme (Marizyme) Net Change in Cash : $-0.32 Mil (TTM As of Mar. 2024)


View and export this data going back to 2008. Start your Free Trial

What is Marizyme Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Marizyme's Net Change in Cash for the three months ended in Mar. 2024 was $-0.14 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.32 Mil.

Marizyme Net Change in Cash Historical Data

The historical data trend for Marizyme's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marizyme Net Change in Cash Chart

Marizyme Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 2.90 1.17 -3.56 -0.36

Marizyme Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.18 -0.13 0.27 -0.33 -0.14

Marizyme Net Change in Cash Calculation

Marizyme's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-4.685+0+4.322+0
=-0.36

Marizyme's Net Change in Cash for the quarter that ended in Mar. 2024

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-0.809+0+0.667+0
=-0.14

Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.32 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Marizyme Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Marizyme's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Marizyme (Marizyme) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marizyme Inc (OTCPK:MRZM) » Definitions » Net Change in Cash
Comparable Companies
BCDA PCSA VRPX CNSP FREQ OGEN ITRM BCEL TOVX BRTX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
555 Heritage Drive, Suite 205, Jupiter, FL, USA, 33458
Website
https://www.marizyme.com
Marizyme Inc is a multi-technology biomedical company dedicated to the accelerated development and commercialization of medical device technologies that improve patient health outcomes. Currently, the company is focused on developing three medical technology products: DuraGraft, Krillase, and MATLOC. DuraGraft is a single-use intraoperative vascular graft treatment that protects against ischemic injury and reduces the incidence and complications of graft failure, MATLOC is a point-of-care, lab-on-chip digital screening, and diagnostic device platform, initially being developed for quantitative chronic kidney disease, or CKD, assessment, and Krillase protein enzyme provides a therapeutics opportunity for wound healing, thrombosis, and pet health.
Executives
Braeden Lichti 10 percent owner 650 GEORGIA ST #3200, VANCOUVER A1 V6B4P7
Nilesh Umedbhai Patel director 555 HERITAGE DRIVE, SUITE 205, JUPITER FL 33458
Michael R Stewart director 5 WALNUT GROVE DRIVE, STE 140, HORSHAM PA 19044
Harrison Ross officer: Vice President of Finance 555 HERITAGE DRIVE, SUITE 205, JUPITER FL 33458
Georgiy Kovalyov officer: Chief Financial Officer 555 HERITAGE DRIVE, SUITE 205, JUPITER FL 33458
David Barthel director, officer: Chief Executive Officer 555 HERITAGE DRIVE, SUITE 205, JUPITER FL 33458
Bradley Richmond officer: Acting VP of Finance 555 HERITAGE DRIVE, SUITE 205, JUPITER FL 33458
Julie B. Kampf director 14054 OLD CYPRESS BEND, PALM BEACH GARDENS FL 33410
Vithalbhai D Dhaduk director FNCB BANCORP, INC., 102 E. DRINKER ST., DUNMORE PA 18512
Neil J Campbell director, officer: Chief Executive Officer 225 CHIMNEY CORNER LANE, SUITE 2001, JUPITER FL 33458
Very Donald Leroy Jr officer: Executive Vice President 4 SILVERWHITE AVENUE, LITTLE SILVER NJ 07739
William Hearl director 448 SALK CIRCLE, GAITHERSBERG MD 20878
Bruce Harmon officer: Chief Financial Officer 316 DEL PRADO BLVD. S., SUITE 204, CAPE CORAL FL 33990
Catherine J. Pachuk officer: Chief Science Officer 1033 N. JEAGA DR, JUPITER FL 33458
Satishchandran Chandrasekhar officer: Chief Operating Officer 167 CARMELA COURT, JUPITER FL 33478